MedTrace Logo

Sublingual Misoprostol to Reduce Blood Loss During Elective Cesarean Delivery

NCT03140033 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2017-05-04

No results posted yet for this study

Summary

Sublingual Misoprostol to Reduce Blood Loss During Elective Cesarean Delivery : A Randomized Controlled Trial

Conditions

  • Hemorrhage Postpartum

Interventions

DRUG

Misoprostol Oral Tablet

at cord clamping the patient will recieve 400 micrograms of misoprostol sublingually

DRUG

Ranitidine Oral Tablet

at cord clamping the patient will recieve ranitidine sublingually

Sponsors & Collaborators

  • Ain Shams Maternity Hospital

    lead OTHER

Principal Investigators

  • Amr H YEHIA, MD,MRCOG · Ain Shams University-Maternity Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03140033 on ClinicalTrials.gov